 |
More: 15th Conference on Retroviruses and Opportunistic Infections (CROI) Incorporating Integrase Inhibitors into Clinical Practice CME February 3 - 6, 2008, Boston, Massachusetts Author Information and Disclosures This activity is not sanctioned by, nor a part of, the 15th Conference on Retroviruses and Opportunistic Infections.
Release Date: March 31, 2008; Valid for credit through March 31, 2009 | Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Incorporating Integrase Inhibitors into Clinical PracticeMartin Markowitz, MD, MSCE; Eric S. Daar, MD; Jurgen K Rockstroh, MD, PhDAvailable As: Slides/Video | Slides/Transcript
Legal DisclaimerThe materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 15th Conference on Retroviruses and Opportunistic Infections. These materials and the related activity are not sanctioned by the 15th Conference on Retroviruses and Opportunistic Infections or the commercial supporter of the conference and do not constitute an official part of that conference. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Describe new data on the antiviral effects of novel antiretrovirals (ARVs) and ARV classes alone and in combination
- Explain the latest data on resistance, resistance testing, and novel cellular and viral targets of new and investigational
ARVs
Authors and Disclosures Martin H. Markowitz, MD
Disclosure: Martin H. Markowitz, MD, has disclosed that he has received grants for clinical research from Gilead, GlaxoSmithKline, Merck, Pfizer, and Tibotec, and that he has served as an advisor or consultant to Gilead, GlaxoSmithKline, Merck, Pfizer, Sequoia, and Tibotec.
Eric S. Daar, MD
Disclosure: Eric S. Daar, MD, has disclosed that he has received grants for clinical research from Abbott, GlaxoSmithKline, Gilead, and Merck. Dr. Daar has also disclosed that he has received grants for educational activities from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Merck, Monogram, Pfizer, Tibotec, and Virco, and that he has served as an advisor or consultant to Abbott, Boehringer
Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead, Merck, Monogram, Pfizer, Tibotec, and Virco. Jurgën K. Rockstroh, MD
Disclosure: Jurgėn K. Rockstroh, MD, has disclosed that he has served as an advisor or consultant to Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Merck, Novartis, Pfizer, Tibotec, Vertex, and Virco. Thomas Maxwell
Mundy, MD
Disclosure: Thomas Maxwell Mundy, MD, has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
